Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Benzoyl peroxide + tazarotene** is a fixed-dose topical combination medication used primarily to treat acne vulgaris. It consists of two active agents: benzoyl peroxide, which is a topical antimicrobial and keratolytic agent that generates free radicals to oxidize bacterial proteins and reduce Propionibacterium acnes colonization, and tazarotene, a third-generation topical retinoid (retinoic acid receptor agonist) that modulates gene expression affecting cell proliferation and inflammation in the skin. The combination leverages the comedolytic, anti-inflammatory, and antibacterial actions of benzoyl peroxide with the keratolytic and anti-comedogenic properties of tazarotene, leading to improved efficacy in treating both inflammatory and non-inflammatory acne lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzoyl peroxide + tazarotene.